A study registered with ClinicalTrials.gov under the identifier NCT05955521, sponsored by Samsung Medical Center, indeed seems to focus on the evaluation of circulating tumour DNA (ctDNA) and exosomes in triple-negative and HER2-positive breast cancer patients who have undergone neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.